EKF Diagnostics Holdings PLC Posting of Annual Report & Notice of AGM (0620M)
May 01 2015 - 10:15AM
UK Regulatory
TIDMEKF
RNS Number : 0620M
EKF Diagnostics Holdings PLC
01 May 2015
1 May 2015
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Posting of Annual Report & Notice of AGM
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care, central laboratory and molecular diagnostics
business, confirms that the Annual Report and Accounts for the year
ended 31 December 2014, the Notice of the Annual General Meeting
and a Form of Proxy have been posted to shareholders.
The AGM is to be held on 19 May 2015 at the offices of Panmure
Gordon, One New Change, London EC4M 9AF at 2pm.
A copy of the 2014 Annual Report and Accounts and other
documents are available on the Company's website:
http://www.ekfdiagnostics.com/
Enquiries:
EKF Diagnostics Holdings Tel: 029 2071 0570
plc
David Evans, Executive Mob: 07740 084 452
Chairman
Julian Baines, CEO Mob: 07788 420 859
Paul Foulger, CFO Mob: 07710 989 255
Panmure Gordon (UK)
Limited
Robert Naylor (Corporate Tel: 020 7886 2714
Finance)
Michael Seabrook (Sales) Tel: 020 7886 2704
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com
EKF Diagnostics Holdings plc was formed in July 2010 following
the acquisition of EKF-diagnostic GmbH for EUR14.32m and refocused
its strategy to one of building a substantial point of care
diagnostics business. As part of this strategy, the Group has
integrated three further acquisitions, Quotient Diagnostics Limited
(acquired in September 2010), Argutus Medical Limited (acquired in
December 2010) and Stanbio Laboratory L.P. (acquired in June 2011).
In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics
Ltd, to focus on molecular and companion diagnostics and acquired
360 Genomics Ltd, a business that owns diagnostics technologies for
cancer gene detection.
The Company, with its head office in Cardiff and operations in
London, Germany, Poland, Russia, Ireland and the US, is a leading
diagnostics business, focussing on the development, production and
distribution of chemical reagents and analysers for the testing of
Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
In March 2011 EKF entered into a distribution agreement with
Alere Inc ("Alere"), a global diagnostics company, under which
Alere was appointed the exclusive distributor of EKF's CLIA waived
Hemo Control device and cuvettes in the US, Canada and United
Kingdom. The device is distributed in the US under the name
HemoPoint H2.
In March 2014, EKF acquired Separation Technology, Inc., a
Florida based manufacturer of in vitro diagnostics devices for the
haematology testing market. In April 2014, EKF completed the
acquisitions of Selah Genomics Inc., a US based developer of
molecular diagnostics for personalised medicine and DiaSpect
Medical AB., a Swedish based manufacturer of point-of-care
haemoglobin analysers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCABMITMBBMBIA
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024